EICHOR
● Recruiting
A Prospective Multicenter Phase 2 Study of FCR/BR Alternating With Ibrutinib in Treatment-naive Patients With CLL
Condition: Chronic Lymphocytic Leukemia · Sponsor: Institute of Hematology & Blood Diseases Hospital, China
About this study
This is a prospective multicenter phase 2 study designed with the purpose to evaluate the response rate and safety of treatment with FCR/BR alternating with ibrutinib in treatment-naive patients with chronic lymphocytic leukemia.
This description comes directly from the study's public registry record.
Talk to the study team
Zengjun Li · +86 13642138692 · lizengjun@ihcams.ac.cn
Tingyu Wang · +86 15692201678 · wangtingyu@ihcams.ac.cn
Always discuss trial participation with your own doctor first.
Locations (1)
| Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College | Tianjin, Tianjin Municipality, China | Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03980002